Meeting
2023 ASCO Genitourinary Cancers Symposium
Antitumor immunity as the basis for durable disease-free, treatment-free survival (DDFTFS) in patients with metastatic urothelial cancer (mUC).
Authors
Jonathan Forrest Anker
Icahn School of Medicine at Mount Sinai, New York, NY
Jonathan Forrest Anker , Sumanta Monty Pal , Seunghee Kim-Schulze , Huan Wang , Rebecca Halperin , Andrew Uzilov , Takuro Saito , Noah M. Hahn , Manishkumar Patel , Jingjing Qi , Hui Xie , Nina Bhardwaj , Sacha Gnjatic , Matt D. Galsky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 536)
DOI
10.1200/JCO.2023.41.6_suppl.536
Abstract #
536
Poster Bd #
L19
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC).
First Author: Matt D. Galsky
Poster
2013 Genitourinary Cancers Symposium
Antioxidant stimulation as the adaptation mechanism in patients with metastatic urothelial cancers (MUC) treated with gemcitabine and cisplatin (GC).
First Author: Patrik Palacka
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.
First Author: Sarmad Sadeghi
Poster
2022 ASCO Annual Meeting
A phase III randomized trial of eribulin (E) with or without gemcitabine versus standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.
First Author: Sarmad Sadeghi